2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

EMT6 cells

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Click Chemistry

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-171658
    R1-ICR-5

    		PROTACs Ser/Thr Kinase TNF Receptor Toll-like Receptor (TLR) NF-κB p38 MAPK Inflammation/Immunology Cancer
    R1-ICR-5 is a highly selective RIPK1 PROTAC degrader. Mediated by VHL, R1-ICR-5 induces the degradation of RIPK1, which in turn dysregulates the TNFR1 and TLR3/4 signaling hubs, enhances the signaling outputs of NF-κB, MAPK and IFN, and simultaneously promotes RIPK3 activation and necroptosis (necroptosis). R1-ICR-5 can be used in the research of triple-negative breast cancer and skin inflammation .
    R1-ICR-5
  • HY-154253
    5-Azidomethyl-2'-deoxyuridine

    5-AmdU; α-Azidothymidine

    		 Nucleoside Antimetabolite/Analog Cancer
    5-Azidomethyl-2'-deoxyuridine (5-AmdU) is a purine nucleoside analog. 5-Azidomethyl-2'-deoxyuridine demonstrates effective radiosensitization in EMT6 tumor cells. . 5-Azidomethyl-2'-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    5-Azidomethyl-2'-deoxyuridine
  • HY-P991481
    S-531011

    		CCR Inflammation/Immunology Cancer
    S-531011 is a human IgG1 monoclonal antibody (mAb) targeting CCR8. S-531011 reduces tumor-infiltrating CCR8+ Tregs and has anti-tumor activity in CT26.WT and EMT6 tumor-bearing mouse tumor models. S-531011 can be used in the study of cancer immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    S-531011
  • HY-150749A
    ODN D-SL03 sodium

    		IFNAR Cancer
    ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
    ODN D-SL03 sodium
  • HY-176834
    3-Deoxy-3-fluoro-D-fructose

    		GLUT Cancer
    3-Deoxy-3-fluoro-D-fructose (Compound 12) is a derivative of 2,5-Anhydro-D-mannitol. 3-Deoxy-3-fluoro-D-fructose is a selective probe of Hexose transporter 5 (GLUT5). 3-Deoxy-3-fluoro-D-fructose inhibits the transport of D-fructose labeled with 14C by GLUT5 with IC50s of 1.16 and 2.37 µM in EMT-6 and MCF-7 cells. 3-Deoxy-3-fluoro-D-fructose can be used for positron emission tomography (PET) imaging of cancers .
    3-Deoxy-3-fluoro-D-fructose
  • HY-124178
    (R)-Levrazoxane

    (R)-ICRF 186

    		 Drug Intermediate Metabolic Disease
    (R)-Levrazoxane ((R)-ICRF 186) is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R)-Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581). (R)-Levrazoxane is promising for research of liver and kidney related diseases .
    (R)-Levrazoxane
  • HY-150609
    SHP2/CDK4-IN-1

    		SHP2 Phosphatase CDK Cancer
    SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and CDK4 dual inhibitor, with IC50 values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research .
    SHP2/CDK4-IN-1
  • HY-116156
    SR-4554

    		Biochemical Assay Reagents Cancer
    SR-4554 is a probe for the measurement of tumor hypoxia. SR-4554 undergoes enzymatic single-electron reduction reactions within hypoxic cells. SR-4554 determines the 19F retention index for four commonly used mouse tumors (EMT6, SCCVII, KILT and RIF-I) through 19F MRS technique. SR-4554 can used to detect tumor Hypoxia noninvasively by 19F magnetic resonance spectroscopy ( 19F MRS) .
    SR-4554
  • HY-150749
    ODN D-SL03

    		IFNAR Inflammation/Immunology Cancer
    ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
    ODN D-SL03
  • HY-182772
    Enpp-1-IN-31

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-31 is a ENPP1 inhibitor with an IC50 of <20 nM (using cGAMP as the substrate). Enpp-1-IN-31 exhibits potential anticancer activity and inhibits the growth and proliferation of mouse colon cancer cells and breast cancer cells .
    Enpp-1-IN-31
  • HY-181919
    CD73-IN-22

    		CD73 Radionuclide-Drug Conjugates (RDCs) Cancer
    CD73-IN-22 (Compound HX-6) is a non-nucleoside CD73 inhibitor with an IC50 of 0.07 μM. When radiolabeled with 68Ga, CD73-IN-22 acts as a PET radiotracer for detecting CD73 expression. When radiolabeled with 177Lu, CD73-IN-22 exhibits anticancer activity against colorectal adenocarcinoma. CD73-IN-22 is applicable to research related to colon adenocarcinoma and breast cancer .
    CD73-IN-22

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: